Ketamine in Adolescents With Treatment-Resistant Depression

Open-label, single-group trial testing serial IV ketamine in adolescents (12–18 years) with treatment-resistant major depressive disorder.

Participants receive six subanesthetic IV infusions of ketamine 0.5 mg/kg over 40 minutes across 2 weeks; primary aims are clinical efficacy and durability through a 4-week observational period.

Secondary aims include investigation of neurobiological mechanisms using brain imaging and peripheral biomarkers to characterise response and non-response in adolescence.